SL1009 (sodium dichloroacetate)

Name: SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Prevalence of Pyruvate dehydrogenase complex deficiency
Published: 2026-09-14T15:39:06-04:00

Pyruvate dehydrogenase complex deficiency

Manufacturer: Saol Therapeutics
Regulatory submission: NDA resubmitted June 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of Pyruvate dehydrogenase complex deficiency

3 evidence topics · 3 sources

U.S. prevalence estimate

“fewer than 1,000 individuals in the U.S.” (opens the source at this quote in a new tab)

Swedish population-based cohort and birth prevalence

“54 patients (35 female patients)” (opens the source at this quote in a new tab)
“birth prevalence of 2.43 per 100,000 live births (95% CI 1.86–3.17)” (opens the source at this quote in a new tab)

Swedish point prevalence

“a point prevalence of 0.44 per 100,000 population (95% CI 0.40-0.65).” (opens the source at this quote in a new tab)